Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label …
CJ Langer, SM Gadgeel, H Borghaei… - The lancet …, 2016 - thelancet.com
Background Limited evidence exists to show that adding a third agent to platinum-doublet
chemotherapy improves efficacy in the first-line advanced non-small-cell lung cancer …
chemotherapy improves efficacy in the first-line advanced non-small-cell lung cancer …
Pembrolizumab plus pemetrexed and platinum in nonsquamous non–small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study
MC Garassino, S Gadgeel, G Speranza… - Journal of Clinical …, 2023 - ascopubs.org
Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically on the based on the primary end point, may be published when key planned …
report, typically on the based on the primary end point, may be published when key planned …
Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non–small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study
SM Gadgeel, JP Stevenson, CJ Langer, L Gandhi… - Lung Cancer, 2018 - Elsevier
Objectives Platinum-based chemotherapy for advanced non–small-cell lung cancer
(NSCLC) has modest benefit overall, but has the potential to amplify immune responses. In …
(NSCLC) has modest benefit overall, but has the potential to amplify immune responses. In …
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non …
MC Garassino, S Gadgeel, E Esteban, E Felip… - The Lancet …, 2020 - thelancet.com
Background Pembrolizumab plus pemetrexed–platinum led to superior overall survival and
progression-free survival, and a higher proportion of patients with a confirmed complete or …
progression-free survival, and a higher proportion of patients with a confirmed complete or …
[HTML][HTML] 24-month overall survival from KEYNOTE-021 cohort G: Pemetrexed and carboplatin with or without Pembrolizumab as first-line therapy for advanced …
H Borghaei, CJ Langer, S Gadgeel… - Journal of Thoracic …, 2019 - Elsevier
Abstract Introduction Cohort G of KEYNOTE-021 (NCT02039674) evaluated the efficacy and
safety of pembrolizumab plus pemetrexed-carboplatin (PC) versus PC alone as first-line …
safety of pembrolizumab plus pemetrexed-carboplatin (PC) versus PC alone as first-line …
Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non–small-cell …
S Gadgeel, D Rodríguez-Abreu, G Speranza… - Journal of clinical …, 2020 - ascopubs.org
PURPOSE In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum
significantly improved overall survival (OS) and progression-free survival (PFS) compared …
significantly improved overall survival (OS) and progression-free survival (PFS) compared …
Pembrolizumab plus pemetrexed‐platinum for metastatic nonsquamous non–small‐cell lung cancer: KEYNOTE‐189 Japan Study
H Horinouchi, N Nogami, H Saka, M Nishio… - Cancer …, 2021 - Wiley Online Library
Pembrolizumab plus pemetrexed‐platinum significantly improved overall survival (OS) and
progression‐free survival (PFS) with manageable safety compared with placebo plus …
progression‐free survival (PFS) with manageable safety compared with placebo plus …
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Background Despite recent advances in the treatment of advanced non-small-cell lung
cancer, there remains a need for effective treatments for progressive disease. We assessed …
cancer, there remains a need for effective treatments for progressive disease. We assessed …
[HTML][HTML] Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final …
D Rodríguez-Abreu, SF Powell, MJ Hochmair… - Annals of …, 2021 - Elsevier
Background In the phase III KEYNOTE-189 study (NCT02578680), pembrolizumab plus
pemetrexed and platinum-based chemotherapy (pemetrexed–platinum) significantly …
pemetrexed and platinum-based chemotherapy (pemetrexed–platinum) significantly …
First-line Pembrolizumab versus Pembrolizumab plus chemotherapy versus chemotherapy alone in non–small-cell lung cancer: a systematic review and network meta …
Background This study aimed to comprehensively review the available evidence regarding
the efficacy of first-line pembrolizumab for advanced/metastatic non–small-cell lung cancer …
the efficacy of first-line pembrolizumab for advanced/metastatic non–small-cell lung cancer …